BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
4/8 — Partial
Priority Review
SYLVANT (siltuximab) by Recordati is interleukin-6 antagonists [moa]. Approved for multicentric castleman's disease. First approved in 2014.
Drug data last refreshed Yesterday
Mechanism of Action
Interleukin-6 Antagonists
Pharmacologic Class:
Interleukin-6 Antagonist
Indications (1)
Clinical Trials (12)
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Started Jan 2025
20 enrolled
Non-Hodgkin LymphomaCytokine Release Syndrome
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Started Nov 2024
215 enrolled
Multiple Myeloma
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
Started Mar 2021
22 enrolled
Idiopathic Multicentric Castleman's Disease
SILtuximab in Viral ARds (SILVAR) Study
Started Nov 2020
555 enrolled
Acute Respiratory Distress SyndromeLung DiseasesPneumonia+2 more
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Started Jan 2020
35 enrolled
Metastatic Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
Worked on SYLVANT at Recordati? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.